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Available online 12 April 2016Drug induced mitochondrial dysfunction has been implicated in organ toxicity and the withdrawal of drugs or
black box warnings limiting their use. The development of highly speciﬁc and sensitive in vitro assays in early
drug development would assist in detecting compounds which affect mitochondrial function. Here we report
the combination of two in vitro assays for the detection of drug induced mitochondrial toxicity. The ﬁrst assay
measures cytotoxicity after 24 h incubation of test compound in either glucose or galactose conditioned media
(Glu/Gal assay). Compounds with a greater than 3-fold toxicity in galactose media compared to glucose media
imply mitochondrial toxicity. The second assay measures mitochondrial respiration, glycolysis and a reserve ca-
pacity with mechanistic responses observed within one hour following exposure to test compound. In order to
assess these assays a total of 72 known drugs and chemicals were used. Dose–response data was normalised
to 100× Cmax giving a speciﬁcity, sensitivity and accuracy of 100%, 81% and 92% respectively for this combined
approach.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
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In vitro1. Introduction
Mitochondria are ubiquitous in most eukaryotic cells and are in-
volved in numerous cellular functions, the most prominent being the
production of cellular energy in the form of adenosine triphosphate
(ATP). Further mitochondria are also involved in fatty acid metabolism,
calcium signalling, cellularmetabolism, steroid synthesis, heme produc-
tion, apoptosis and autophagy (reviewed by Nunnari and Suomalainen,
2012; Schefﬂer, 2001). Disturbances in mitochondrial function have
been shown to lead to diseases and metabolic disorders such as Leber's
hereditary optic neuropathy, caused by mutations in genes encoding
subunits of complexes I, III and IV of the electron transport chain
resulting in blindness (Howell et al., 1991; Holt et al., 1989; Martin,
2012). Furthermore, mutations of DNA polymerase ɣ are linked tomito-
chondrial disease and liver injury (Muller-Hocker et al., 2011).
Although not conclusive, there is evidence that drug induced mito-
chondrial dysfunctionmay play a role in drug induced liver, central ner-
vous system, cardiac and skeletal muscle toxicity (Masubuchi et al.,
2002; Oliveira et al., 2004; Kaufmann et al., 2006; Westwood et al.,
2005 and reviewed byDykens et al., 2007) resulting in eitherwithdraw-
al or limitations on market use.
Inhibition of mitochondrial β-oxidation of fatty acids by compounds
can result in microvesicular steatosis (Freneaux et al., 1990) or. This is an open access article underinhibition of complex I of the electron transport chain (ETC) by
phenformin and metformin, which has been associated with lactic aci-
dosis and liver injury (Dykens et al., 2008). Direct links between drug in-
duced organ toxicity and effects on mitochondrial function was ﬁrst
described for the nucleotide reverse transcriptase inhibitors (NRTIs),
where itwas shown that they inhibitmitochondrial biogenesis resulting
in pathologies such as lactic acidosis, lipodystrophy and fulminant liver
failure (Lewis et al., 1992 and reviewed by White, 2001). There have
been several high proﬁle withdrawals of compounds from the market
which have been linked to effects on mitochondrial function.
Troglitazone was withdrawn by the U.S. Food and Drug Administration
(FDA) in 2000 due to its severe liver toxicity (http://www.fda.gov;
Jaeschke, 2007; Tirmenstein et al., 2002) and cerivastain in 2001 due
to rhabdomyolysis (http://www.fda.gov, Furberg and Pitt, 2001;
Kaufmann et al., 2006), alongwith a black box warning for pioglitazone
(http://www.fda.gov). As such over the past few years a number of
in vitro assays have been developed to assess new chemical entities
(NCEs) and their potential to cause mitochondrial toxicity. One ap-
proach measures and compares cytotoxicity of compounds on cells in
different media containing either high glucose or galactose
(Marroquin et al., 2007). Taking advantage of a phenomenon known
as the Crabtree effect (Crabtree, 1928; Ibsen, 1961), in which cells rely
on glycolysis as a main energy source in the presence of high levels of
glucose or switch to oxidative phosphorylation for ATP production
when glucose is substituted with galactose, which is ATP neutral during
glycolysis (Rodriguez-Enriquez et al., 2001; Diaz-Ruiz et al., 2011).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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effects of mitochondrial toxicants, such as rotenone, compared to cells
cultured in glucose conditions (Marroquin et al., 2007). This principle
can be used in cytotoxicity assays, using cell healthmarkers to compare
the relative sensitivity of glucose versus galactose maintained cells
(Dykens et al., 2007). Non-invasive, label freemethodshave been devel-
oped tomeasure oxygen consumption as a direct indicator ofmitochon-
drial function. Platforms such as the extracellular ﬂux analyser (XF ﬂux
analyser, Seahorse Biosciences, Billericia, MA), or the use of ﬂuorescent-
ly labelled oxygen and pH sensing probes (Hynes et al., 2006; O'Riordan
et al., 2007) are replacing the low throughput Clarke electrode. These
approaches allow the determination of changes in cellular metabolism
(Wu et al., 2007; Hynes et al., 2006). Furthermore, by incorporating a
mitochondrial stress test, as described by Brand and Nicholls (2011) it
is possible to gain an understanding of mitochondrial reserve capacity,
which is the difference between basal oxygen consumption rate (OCR)
and the maximal achievable OCR. Reserve capacity can be determined
when cells are treated with the uncoupling agent carbonyl cyanide 4-
(triﬂuoromethoxy) phenylhydrazone (FCCP), which allows the free
movement of electrons along the electron transport chain with the con-
comitant increase in oxygen consumption.It has been reported that re-
serve capacity can be a marker of cellular stress and an indicator of
mitochondrial dysfunction (Dranka et al., 2010; Brand and Nicholls,
2011).
Detection of potential drug induced mitochondrial dysfunction
using in vitro assays allows the selection of chemical serieswithminimal
liability for mitochondrial toxicity at early stages of drug development.
Here we report data from two in vitro assays compared against a refer-
ence set of compounds to predictmitochondrial toxicity. In addition,we
describe how these data can be used to gain insight into potential mode
of action of mitochondrial toxicants.
2. Materials and methods
2.1. Materials
Compounds were purchased from Sigma-Aldrich (Dorset, UK) with
the exception of clozapine, paroxetine (Abcam plc Cambridge, UK),
2,4-dinitrophenol, bosentan, ﬁaluridine, oligomycin (Santa Cruz Bio-
technology Inc., Heidelberg, Germany) and entacapone (Sequoia Re-
search Products Limited, Pangbourne, UK). The XFe96 FluxPaks for the
XFe96Extracellular Flux Analyzerwere purchased fromSeahorse Biosci-
ences (North Billerica,MA, USA). All cell culturemedia and supplements
were from Fisher Scientiﬁc (Loughborough, UK).
2.2. Cell culture
The human hepatoblastoma cell line HepG2was obtained from Pub-
lic Health England European Collection of Cell Cultures (ECACC,
Salisbury, UK). Cells were cultured in completeMinimal EssentialMedi-
um (EMEM) supplemented with 10% foetal bovine serum (FBS), 2 mM
L-GlutaMAX, 1% non-essential amino acids (NEAA), 53 U/mL penicillin
and 53 μg/mL streptomycin. Cells were maintained in a humidiﬁed at-
mosphere with 5% CO2 at 37 °C. Cells were passaged three times a
week and kept in culture for up to four weeks.
2.3. Assessment of mitochondrial toxicity using glucose and galactose
selective media conditions (Glu/Gal assay)
Mitochondrial toxicity was assessed in HepG2 cells using glucose
and galactose conditioned media and the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay as a
read out for cell viability. This method was based on the protocol pub-
lished by Marroquin et al. (2007) with some modiﬁcations. In brief,
cells were seeded onto 96 well, clear bottom tissue culture plates at adensity of 10,000 cells/well and left overnight to attach. Six hours
prior to the compound treatment the media was replaced with 100 μL
Dulbecco Modiﬁed Eagle Medium (DMEM) media containing either
glucose (25 mM glucose; 1 mM pyruvate; 2 mM glutamine, 10% FBS,
1% NEAA) or galactose (10 mM galactose, 1 mM pyruvate, 6 mM gluta-
mine, 10% FBS, 1% NEAA). Compoundswere prepared at a 200-fold ﬁnal
concentration in appropriate vehicle (0.5% v/v ﬁnal concentration).
Compounds were serially diluted in appropriate vehicle to give an
eight point concentration curve using a half-log dilution series. Dosing
solutions were prepared by diluting the compound stocks 1:40 in the
appropriate assay media (Glucose or Galactose) and the cells were
dosed by adding 25 μl of the dosing solution to the appropriate wells.
Compound incubation was performed for 24 h in a humidiﬁed atmo-
spherewith 5% CO2 at 37 °C. After compound treatment cells were load-
ed with MTT dye with a ﬁnal concentration of 0.5 mg/mL MTT and
incubated for 1 h in a humidiﬁed atmosphere with 5% CO2 at 37 °C. Su-
pernatants were removed and the plates were left to dry before cells
were re-solubilised in 100 μL of DMSO. Absorbance was read at
570 nm using an absorbance plate reader (SpectraMax Plus, Molecular
Devices).2.4. Measurement of mitochondrial toxicity using an extracellular ﬂux
assay
An extracellular ﬂux assay was used to assess mitochondrial tox-
icity in HepG2 cells by determining the oxygen consumption rate
(OCR), reserve capacity, and extracellular acidiﬁcation rate (ECAR)
utilising the XFe96 ﬂux analyzer (Seahorse Biosciences), as described
by Brand and Nicholls (2011). In brief, HepG2 cells were seeded at
20,000 cells/well onto XFe96 plates (Seahorse Biosciences) and left
overnight to attach. The cells were washed twice in un-buffered
DMEM assay medium (Sigma-Aldrich) supplemented with 10 mM
glucose, 30 mM NaCl, 1 mM pyruvate, 2 mM L-alanyl-glutamine
(medium pH 7.4, 37 °C). Cells were then incubated in 180 μL assay
media in a CO2 free incubator at 37 °C for 60 min. Test compounds
were prepared at 200-fold ﬁnal concentration in appropriate vehicle
(either DMSO or water). Compounds were serially diluted to form a
seven point half-log dilution series and were further diluted 1:10 in
assay media. The XFe 96 microplate cartridges were loaded with
20 μL of dosing solution. The ﬁnal DMSO concentration in all incuba-
tions was 0.5% (v/v ﬁnal volume). Four initial baseline OCR and ECAR
measurements prior to the addition of test compound were deter-
mined. Each measurement consisted of a three minute mix and
four minute read cycle. Following treatment with the test compound
a further six measurements of OCR and ECAR were taken. Subse-
quently a mitochondrial stress test was performed by consecutive
addition of the ATP synthase inhibitor, oligomycin (1 μM), the un-
coupler, carbonyl cyanide 4-(triﬂuoromethoxy) phenylhydrazone
(FCCP, 0.5 μM) and ﬁnally the ETC inhibitors rotenone (1 μM) plus
antimycin A (1 μM) (Rot/AA). Two subsequent OCR measurements
were taken following each inhibitor addition. Basal OCR, the sixth
OCR measurement following compound or vehicle addition, were
normalized to the baseline OCR measurements, and all measure-
ments were corrected for the non-mitochondrial OCR (the ﬁnal
OCR measurement following the addition of Rot/AA). Reserve capac-
ity is deﬁned as the maximal OCR and was determined as change
from the baseline OCR, and corrected for the non-mitochondrial
OCR following FCCP addition. ECAR measurements were taken after
the addition of vehicle or test compound and normalized to baseline
ECAR. On each plate 10 wells were cell free, four were used as tem-
perature control wells and the remaining 6 wells were used as com-
pound control wells. In brief, the top concentration of test compound
was injected as described above to identify interference of com-
pound with either OCR or ECAR due to pH changes or compound
colour.
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Data was normalized to vehicle control and for each compound
dose–response curves were deﬁned and evaluated with the following
equations:
ξ C; c;ωð Þ ≡ ln Cð Þ–cð Þ=ω;
t ξð Þ ≡ 1þ tanh ξð Þð Þ=2;
R t;R0;R∞ð Þ ≡ R0 1−tð Þ þ R∞t:
In which C represents the test compound concentration and R0, R∞,
c, andω are ﬁtting parameters. The ﬁnal response at a given concentra-
tion C is expressed as R(t(ξ(C; c;ω));R0;R∞). It was restricted such that
ω N 0, which implies R→ R0 as C→ 0 and R→ R∞ as C→ ∞. The lowest
concentration exceeding the vehicle control limits (0.85–1.15 of the ve-
hicle control values) were deﬁned as theminimum effective concentra-
tion (MEC). The concentration, which results in 50% response, was
deﬁned as an AC50 value and calculated according to historical data for
maximal responses. The coefﬁcient of determination (R2) wasFig 1. Representative graphs demonstrating the fold shift in sensitivity of HepG2 cells dosed in
(10.4 fold) and (B) perhexiline (1.3 fold). Data is expressed as mean ratio to vehicle control ± S
plateau. Using 72 reference compounds the speciﬁcity (97%, circles), sensitivity (51%, triangles)
a threefold shift in galactose sensitivity (C). Using the 59 compounds with available human C
speciﬁcity, sensitivity and accuracy respectively (D).calculated for each compound and each feature assessed. Responses
with a R2 value smaller than 0.65 were rated as non-signiﬁcant and
were not considered a true response.
Compoundswere classiﬁed asmitochondrial toxicants if the toxicity
of the compound in HepG2 cells cultured in galactosewas 3-fold greater
than those cultured in glucose, or if a dose dependent increase or de-
crease in OCR, ECAR or reserve capacity was determined. If a decrease
in OCR, ECAR and reserve capacity was detected simultaneously the re-
sponse was considered as cytotoxicity.
Sensitivity, speciﬁcity and accuracy of the in vitro assays and the
combined approach were evaluated using the statistics described by
Cooper et al. (1979). The number of true positive (TP), true negative
(TN), false positive (FP) and false negative (FN) was assessed by com-
paring experimental data with available in vivo data from the literature
(refer to Supplementary Table 1).
The Cooper's statistics were calculated using following equations:
Sensitivity in% ¼ TPð Þ= TPþ FNð Þ  100
Specificity in% ¼ TNð Þ= TNþ FPð Þ  100media containing galactose (squares) compared to glucose (circles) with (A) entacapone
D, n= 3. Open symbols represent data points not used in the curve ﬁt analysis due to data
and accuracy (72%, squares) of mitochondrial toxicity predictionwas established based on
max date a 100× Cmax cut-off gave a 100% (circles), 41% (triangles), and 73% (squares) in
Table 1
The Glu/Gal assay sensitivity, speciﬁcity and accuracy mitochondrial toxicity predictions comparing three-fold shift in galactose sensitivity with either no concentration based cut-off or
100× Cmax cut-off. Data were compared to in vivo data available from literature. Number of false predicted compounds are given (FP = false positive, FN = false negative).
Cut-off Sensitivity
(%)
Speciﬁcity
(%)
Accuracy
(%)
Incorrectly predicted
(FP/FN)
Drug and chemical data set (72 compounds) 3 fold shift 51 97 72 20 (1/19)
Drugs with Cmax available (59 compounds) 3 fold shift, 100× Cmax 41 100 73 16 (0/16)
164 J. Eakins et al. / Toxicology in Vitro 34 (2016) 161–170Accuracy in% ¼ TNþ TPð Þ= TNþ TPþ FNþ FPð Þ  100:
3. Results
3.1. Validation set of test compounds
A set of reference compounds and chemicals was selected from the
literature according to their known effects on mitochondria in vivo or
in vitro. The reference compounds consisted of 39 compounds with
known in vivo or in vitromitochondrial liability and 33 with no known
mitochondrial toxicity associated (see Supplemental Table 1). Literature
Cmax datawere available for 59 of the test compounds, of which 27were
associated with organ toxicity with a mitochondrial liability covering a
range of different mechanisms of mitochondrial toxicity and 32 with
no knownmitochondrial liability, but may have known organ toxicities
or considered to be safe. The 13 compoundswithout available Cmax data
included classical mitochondrial toxicants such as antimycin A,
myxothiazol, oligomycin and 2,4-dinitrophenol (Supplementary
Table 1).
3.2. Themeasurement of cytotoxicity in HepG2 cells grown in either glucose
or galactose to identify mitochondrial toxicants (Glu/Gal assay)
Mitochondrial toxicity of test compounds was assessed in HepG2
cells cultured in galactose or glucose containing media. Cell viability
was measured using the MTT assay after a 24 h treatment with the
test compound. Compounds causing a fold shift equal to or greater
than 3were classed asmitochondrial toxicants. Fig. 1 shows representa-
tive dose response curves for entacapone, a known uncoupler of oxida-
tive phosphorylation in vitro (Nadanaciva et al., 2012) (Fig. 1A) and
perhexiline, a negative compound for mitochondrial toxicity (Fig. 1B).
Under galactose conditions HepG2 cells were shown to be more sensi-
tive towards entacapone compared to cells cultured in glucose media
resulting in a 10.4 fold shift of the dose response curves (Fig 1A). Expo-
sure of HepG2 cells to perhexiline showed similar dose response curves
in either media condition (Fig 1B), suggesting that the observed cyto-
toxicity for perhexiline is not related to mitochondrial dysfunction.
The Glu/Gal assay identiﬁed 21 of the 39 positive compounds and only
one as false positive. A summary of the AC50 values and fold shifts are
given in Supplementary Table 1.
Data was assessed by applying cut-offs based on concentration or
in vivo exposure (Cmax), analysis of the complete data set indicated
that a 3-fold shift provides themost predictive cut-off with a sensitivity
of 51%, speciﬁcity of 97% and an overall accuracy of 72% (Fig 1C and
Table 1). The greatest predictivity was shown when the data was nor-
malized to 100× Cmax with a speciﬁcity of 100%, a sensitivity of 41%Table 2
The extracellular ﬂux assay sensitivity, speciﬁcity and accuracy, comparing Cmax cut-off with co
erature. Number of false predicted compounds are given (FP = false positive, FN = false nega
Cut-off Sensitiv
(%)
Drug and chemical data set (72 compounds) 50uM 64
Drugs with Cmax available (59 compounds) 100× Cmax 78and accuracy of 73% (Fig 1D and Table 1). A concentration based cut-
off did not show any improvements, as the highest predictivity was ob-
tained using a cut-off of 10 mM (maximum top concentration) with a
sensitivity, speciﬁcity and accuracy of 41%, 97% and 67% respectively
(Supplementary Fig 1).
3.3. Use of the extracellular ﬂux assay to detect mitochondrial toxicants
Potential mitochondrial toxicants can be determined by measuring
basal OCR and basal ECAR after compound treatment using the XFe96
ﬂux analyser and reserve capacity by using a mitochondrial stress test.
HepG2 cells were able to correctly identify 21 of the 27 compounds as
mitochondrial toxicants. Representative data are shown in Fig. 2 for
antimycin A (Fig 2A), tolcapone (Fig 2B), ﬂutamide (Fig 2C) and
perhexiline (Fig 2D). Both antimycin A and ﬂutamide showed a drop
in basal OCR, and reserve capacity with an associated increase in
ECAR, indicating the inhibition of mitochondrial respiration. Exposure
to tolcapone, a known uncoupler of oxidative phosphorylation, resulted
in a dose dependent increase in both basal OCR and ECAR, and a de-
crease in reserve capacity. Perhexiline, a fatty acid oxidation inhibitor,
decreased both OCR and reserve capacity, but did not show any re-
sponse in ECAR apart from compound related changes in pH (data not
shown).
The extracellular ﬂux assay was assessed to determine if suitable
cut-off criteria would improve the predictivity of mitochondrial toxi-
cants. Therefore the sensitivity, speciﬁcity and overall accuracy were
calculated based on a range of Cmax values and a concentration based
cut-off (See Table 2). The most predictive concentration cut-off was
50 μM (Fig 2E, and Table 3), providing 64% sensitivity, 82% speciﬁcity,
and 72% accuracy. Dose response normalized to 100× Cmax resulted in
a sensitivity of 78%, speciﬁcity of 100% and an overall accuracy of 90%.
Nineteen of the 27 test compounds with known mitochondrial toxicity
were predicted based on either basal OCR or basal ECAR readings (Fig. 3,
diagonal stripes). Incorporation of the stress test, which allows the anal-
ysis of the reserve capacity, correctly identiﬁed a further two positive
compounds, amiodarone and clotrimazole (Fig. 3, black). In combina-
tionwith the stress test a total number of 21 of 27 compoundswere cor-
rectly predicted as mitochondrial toxicants. Six compounds did not
show any changes in either OCR, ECAR or reserve capacity (Fig. 3, dot-
ted). A data summary of the complete compound set and responses is
given in Supplementary Table 1.
3.4. Using an extracellular ﬂux assay can provide insight into the
mechanism of toxicity
Themitochondrial stress test allows the further analysis of themode
of action of the mitochondrial toxicant. Identiﬁcation of signature
changes in OCR, reserve capacity and ECAR were determined from anncentration based cut-off (50 μM). Data were compared to in vivo data available from lit-
tive).
ity Speciﬁcity
(%)
Accuracy
(%)
Incorrectly predicted
(FP/FN)
82 72 20 (6/14)
100 90 6 (0/6)
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upon themechanism of action (Table 3). Unique OCR, ECAR and reserve
capacity proﬁles of four well characterised mitochondrial toxicants are
shown in Fig. 4. Rotenone (Fig. 4A) is a known complex I ETC inhibitor
resulting in a dose depended inhibition of both OCR and reserveFig 2. Extracellularﬂuxwas determined inHepG2 cells cultured in 10mMglucose, 1mMpyruva
A, (B) tolcapone, (C) ﬂutamide and (D) perhexeline on OCR (circles), reserve capacity (squares)
symbols represent data points not used in the curve ﬁt analysis due to either data plateau or pH
circles), sensitivity (64%, triangles) and accuracy (72%, squares)was shownwith a 50 μMconcen
100% (circles), sensitivity of 78% (triangles) and accuracy of 90% (squares) was established witcapacity, whilst a dose dependent increase in ECAR was observed.
Oligomycin, an inhibitor of ATP synthase, resulted in dose dependent
decrease in OCR with a concomitant increase in ECAR, however unlike
the ETC inhibitor, the reserve capacity is not reduced (Fig 4B). The
uncoupling agent 2,4-dinitrophenol increased OCR and ECAR in a dosete and 2mMglutamine. Representative graphs demonstrating the effects of (A) antimycin
and ECAR (triangles). Data is expressed asmean ratio to vehicle control± SD, n=2. Open
/compound colour effects. Using the 72 reference compounds the highest speciﬁcity (82%,
tration cut-off (E). Using the 59 compoundswith available human Cmax data a speciﬁcity of
h a 100× Cmax cut-off (F).
Table 3
Mechanistic prediction based on extracellular ﬂux assay bioenergetic proﬁles, changes in
OCR and ECAR may be bi-directional, and in combination with reserve capacity can be
used to identify potential mechanism. ↑= increase compared to vehicle control, ↓=
decrease compared to vehicle control, NR = no response compared to vehicle control.
Compound Mechanism Direction of change
OCR Reserve Capacity ECAR
Rotenone Complex I inhibitor ↓ ↓ ↑
Antimycin A Complex III inhibitor ↓ ↓ ↑
Oligomycin ATP synthase inhibitor ↓ NR ↑
2,4 dinitrophenol Uncoupler ↑ NR ↑
Bosentan cytotoxic ↓ ↓ ↓
Betaine Negative NR NR NR
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mazole represents an example of a substrate inhibitor for glycolysis
(Fig 4D). Themetabolic proﬁle shows reduced levels of OCR and reserve
capacity, but no effect on ECAR levels. Analysis of bioenergetic proﬁles of
the complete compound set allowed the assignment of potential mech-
anisms using anun-biased approach, identifying compounds as possible
inhibitors of oxidation (ETC inhibitors), uncouplers, ATP synthase inhib-
itors and substrate inhibitors (including glycolysis inhibitors and pyru-
vate transport inhibitors). Mechanisms which were not necessarily a
direct effect on mitochondrial function such as changes in membrane
potential, inducers of oxidative stress and the membrane permeability
transition pore were classiﬁed as “others”. Cytotoxic compounds, such
as bosentan, typically show a decrease in OCR, reserve capacity and
ECAR and compounds with no response observed, such as betaine,
were classiﬁed as negative compounds. Included in the set of com-
pounds were also inhibitors of fatty acid oxidation, etomoxir,
perhexiline and salicylic acid. Although the extracellular ﬂux assay
failed to detect salicylic acid, both etomoxir and perhexiline were iden-
tiﬁed as inhibitors of mitochondrial function (Fig 2D). Both compounds
inhibited both OCR and reserve capacity, etomoxir, unlike perhexiline
showed an increase in ECAR (Supplementary Fig 2). Interestingly the
Glu/Gal assay failed to detect any of the fatty acid oxidation inhibitors
(Supplementary Table 1). Comparison of the potential mechanism
assigned using the stress test with data from the literature indicated
that an extracellular ﬂux assay predicted 76% of the mechanisms accu-
rately (Table 4).
3.5. Combining an extracellular ﬂux assay with the Glu/Gal assay improves
predictivity to detect potential in vivo mitochondrial liability
On combining the prediction from both assays when normalized to
100× Cmax only ﬁve of 57 compounds were predicted as false negatives
which were metformin, paraquat, paroxetine, primaquine, and
promethazine. The combined approach showed an increase in sensitiv-
ity from 41% (Glu/Gal assay) and 78% (extracellular ﬂux assay) to 81%
with a speciﬁcity of 100%. The results for the in vivomitochondrial pos-
itive compounds and the predictions obtained from the single assays
and the combined approach are shown in Table 5.
4. Discussion
In this study we show the prediction of known mitochondrial toxi-
cants by two in vitro methods using the human hepatoblastoma cell
line HepG2, ﬁrstly cytotoxicity in glucose compared with galactose
media (Glu/Gal) and secondly themeasurement of mitochondrial func-
tion using an extracellular ﬂux assays (EFA). Both assays were used to
screen 72 reference compounds and the associated predictivities of mi-
tochondrial toxicitywere determinedwith either a concentration based
or in vivo exposure (Cmax) cut-off. The reference compounds with avail-
able Cmax data contained 27 known in vivomitochondrial toxicants and
32 negatives. Both test methods showed a speciﬁcity of 100%, however
the Glu/Gal assay had a sensitivity and accuracy of 41% and 73% respec-
tively, whilst the EFA showed 78% and 90%, respectively. Combining
data from both assays maintained the speciﬁcity of 100% and the sensi-
tivity and accuracy were increased to 82% and 92% respectively. This
combined approach correctly identiﬁed 22 of the 27 in vivomitochon-
drial toxicants and all of the 32 negative compounds.
The Glu/Gal assay identiﬁed classical mitochondrial toxicants such as
rotenone (1064-fold shift), carbonyl cyanide 3-chlorophenylhydrazone
(CCCP, 16-fold shift) and antimycinA (222-fold shift), as positive in accor-
dance with the literature (Kamalian et al., 2015; Marroquin et al., 2007,
see Supplementary Table 1). A fold shift cut-off of ≥3 betweenAC50 values
of glucose and galactose conditioned media was established as the most
predicative approach in this study. In a previous study a 2-fold shift was
utilised (Swiss et al., 2013), this approach would have resulted in four
false positive, whereas with 3-fold only risperidone was predicted as afalse positive (Table ﬁve) increasing the overall accuracy to 72% (Fig. 1).
Marroquin et al. (2007) reported that risperidone was more toxic
to HepG2 cells in galactose media compared to glucose media at concen-
trations greater than 100× Cmax, which is in agreementwith our ﬁndings.
The predictivity of the Glu/Gal assay with 37 correctly predicted com-
pounds gave a sensitivity of 51% and speciﬁcity of 97%. Normalising the
results to 100×Cmax enabled all negative compounds to be correctly iden-
tiﬁed resulting in a speciﬁcity of 100%, whilst 16 compounds were pre-
dicted as false negatives to give a 41% sensitivity and 73% accuracy.
Previously, meﬂoquine, menadione, pioglitazone, rosiglitazone and ta-
moxifen were reported by Rana et al. (2011) as false negative in the
Glu/Gal assay using rat cardiomyocyte-derived cell line H9c2. Further-
more, Swiss et al. (2013) had reported the misclassiﬁcation of pioglita-
zone, rosiglitazone and tamoxifen using the human myelogenous
leukaemia cell line K562, conﬁrming the ﬁndings of Rana et al. (2011).
The known mitochondrial toxicants amiodarone, diclofenac and
troglitazone were previously positively identiﬁed in HepG2 cells using a
modiﬁed Glu/Gal approach by Kamalian et al. (2015), however Luo
et al. (2012) had reported that inHepG2 cells, following a 24 h compound
incubation, did not detect either amiodaroneor diclofenac, as shownhere.
Troglitazone has also previously been identiﬁed by Swiss et al. (2013) as a
cytotoxic compound rather than a mitochondrial toxicant. The Glu/Gal
assay failed to detect perhexiline, a fatty acid oxidation inhibitor, as a mi-
tochondrial toxicant, but identiﬁed this as a cytotoxic agent. Thisﬁnding is
in accordance with those of Kamalian et al. (2015).
Entacapone and tolcapone are chemically related compounds, how-
ever, tolcapone is known to be more toxic in vivo (Haasio et al., 2002;
Korlipara et al., 2004). Kamalian et al. (2015) has reported less cytotoxic
effects of entacapone in HepG2 cells following 2 or 4 h exposure if com-
pared to tolcapone, but both compounds were predicted as mitochon-
drial toxicants. Conversely, under the conditions detailed here similar
AC50 values were found under galactose conditions but tolcapone
showed more cytotoxicity under glucose conditions than entacapone,
resulting in a 10.4-fold shift in toxicity for entacapone and 3.7-fold
shift for tolcapone. Compared to results published by Kamalian et al.
(2015), our data would indicate increased cytotoxicity at longer expo-
sure times (24 h) in glucose conditions, but not galactose conditions
by tolcapone. The FDA has issued a “black-box warning” for tolcapone
due to hepatotoxicity (as reviewed by Truong, 2009),whilst entacapone
has only been associatedwithmild serum level increases but no liver in-
jury (Watkins, 2000). The discrepancy in the in vitro ranking of these
two compounds compared to the in vivo ranking, based on the magni-
tude of the shift may also be due to human exposure levels. Tolcapone
has a human exposure of 14 μM(Persson et al., 2013)whilst entacapone
has a 3.5 fold lower exposure of 4 μM (Khetani et al., 2013) and is thus
less likely to exhibit the toxicity observed with tolcapone.
Directmeasurement ofmitochondrial respiration has beenwell doc-
umented (Swiss et al., 2013; Hynes et al., 2006) as a sensitive marker of
mitochondrial toxicity. Assessment ofmitochondrial toxicants inHepG2
cells using an extracellular ﬂux assay normalised to 100× Cmax gave no
false positives, and only six false negatives with a speciﬁcity of 100%,
Fig. 4. Unique bioenergetic proﬁles are generated using the extracellular ﬂux assay, which can
basal OCR (circles) and ECAR (triangles) were taken from the sixth measurement following
mitochondrial stress test. The Electron Transport Chain (ETC) inhibitor rotenone has a dose de
the ATP synthase inhibitor, inhibits OCR, and increases ECAR, but has no effect on reserve ca
signiﬁcant effect on the reserve capacity compared to vehicle control (C). Clotrimazole, a glyco
Fig 3. The number of compounds detected from the extracellular ﬂux assay by either OCR,
ECAR and reserve capacity alone or in combination. A compoundwas identiﬁed as positive
if the AC50 of anymeasured parameter was below 100× Cmax. The extracellular ﬂux assay
identiﬁed 21 out of 27 positive in vivo mitochondrial toxicants. Diagonal lined boxes
represent compounds which are positive in conjunction with another parameter. Dotted
boxes indicate false negative compounds. A black box are compounds uniquely
identiﬁed by that feature.White boxes represent compounds not identiﬁed by the feature.
167J. Eakins et al. / Toxicology in Vitro 34 (2016) 161–170accuracy of 90% and sensitivity of 78%. Measuring the effects of com-
pounds on basal OCR and ECAR alone, the EFA identiﬁed 19 of the 27
in vivo positive compounds. Diclofenac was unique in that it showed a
decrease in ECAR and reserve capacity but no changes on OCR.
Diclofenac has been shown to inhibit lactate formation in a glioma cell
line GL261 (Chirasani et al., 2013), to inhibit mitochondrial membrane
potential and induce the mitochondrial permeability transition pore
(Masubuchi et al., 2002). Changes in membrane potential would com-
promise the cells ability to respond to an increased energy demand, af-
fecting the reserve capacity, indicating that the cells are at the
bioenergetic limit due to a mitochondrial impairment (Brand and
Nicholls, 2011). Reserve capacity is important in tissues where there is
sudden changes in ATP demand, such as muscle, neuronal and cardiac
tissues (Yadava and Nicholls, 2007; Dranka et al., 2010). Patients with
cardiovascular diseases due to diabetes have been shown to have im-
paired respiratory capacity, changes in mitochondrial ultrastructure
and expression of respiratory chain complexes (Anderson et al., 2009
and reviewed by Bugger and Abel, 2010), which may render these pa-
tients more susceptible to effects of compound induced mitochondrial
effects. Assessment of reserve capacity was recently shown to identify
potential mitochondrial effects for the endothelin receptor antagonists,be used to provide potential mechanistic understanding of the toxicity. Measurement of
the injection of test compound. Reserve capacity (squares) were taken following the
pendent decrease in OCR and reserve capacity, with an increase in ECAR (A). Oligomycin,
pacity (B). The uncoupler, 2,4-dinitrophenol, increased both OCR and ECAR, but had no
lysis inhibitor, inhibited both OCR and reserve capacity, with no change in ECAR (D).
Table 4
Extracellular ﬂux assay to assign the potential mechanism of action (50 μM cut-off), gave an accuracy of 77% on comparison to literature described mechanisms of action.
Actual Mechanism
ETC inhibitor Uncoupler Substrate inhibitor ATP synthase inhibitor Other None Fatty acid oxidation inhibitor
Predicted mechanism ETC inhibitor 11 0 1 1 1 5 1
Uncoupler 0 5 0 0 0 0 0
ATP synthase 0 0 0 1 0 0 0
Substrate inhibitor 1 0 1 0 0 1 1
Other 0 0 0 0 1 0 0
None 8 3 1 0 1 27 1
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Huh7, a human hepatoma cell line, to the hepatotoxic sitaxentan and
not in the structurally related, but non-toxic ambrisentan (Kenna
et al., 2015). Analysing reserve capacity in HepG2 cells identiﬁed amio-
darone, and clotrimazole, both showing no changes in basal OCR and
ECAR readings. Clotrimazole was also shown to be negative in a recent
publication by Wang et al. (2015) using OCR and ECAR measurements
alone.
Bioenergetic proﬁles for each compound were determined using an
extracellular ﬂux assay, which allowed the identiﬁcation of potential
mechanisms of toxicity and can help to discriminate between the inhib-
itors of oxidation through complex I to IV of the electron transport chain
and ATP synthase. One interesting class of compounds were the fatty
acid oxidation inhibitors including etomoxir and perhexiline, known
to cause hepatotoxicity viamitochondrial dysfunction (Freneaux et al.,
1990; Deschamps et al., 1994; Vickers, 2009). These compounds were
accurately predicted as mitochondrial toxicants with an EFA, but were
misclassiﬁed in the Glu/Gal assay. Etomoxir showed the samemetabolic
proﬁle as ETC inhibitors, whilst perhexiline was classiﬁed as a substrate
inhibitor. However both EFA and the Glu/Gal assay failed to detect
salicylic acid, as a mitochondrial toxicant at concentrations of
4000 μM, however, cytotoxicity was observed at concentrations of
1200 μM and above in the EFA. Previously Nadanaciva et al. (2012)Table 5
Summary table of compounds correctly predicted in either the extracellular ﬂux assay, the Glu
100× Cmax concentration cut-off. The extracellular ﬂux assay AC50 values are shown for OCR,
AC50 value (μM). The fold-change in sensitivity in galactose compared to glucose media are sh
Extracellular ﬂux assay
Compound In vivo Cmax (μM) First mechanism AC
Correctly predicted in the extracellular ﬂux assay but not the Glu/Gal assay
Diclofenac + 6.40 ECAR 23
Meﬂoquine + 2.75 ECAR N3
Menadione + 4.88 OCR 10
Nitrofurantoin + 6 ECAR 43
Perhexiline + 2.16 Res Cap 12
Pioglitazone + 2.72 Res Cap 17
Rosiglitazone + 0.86 Res Cap 5.8
Tamoxifen + 1.21 Res Cap 9.5
Troglitazone + 6.39 Res Cap 1.9
Correctly predicted by the stress test only
Amiodarone + 1.17 Res Cap 32
Clotrimazole + 0.09 Res Cap 2.2
Correctly predicted by the Glu/Gal assay but not the extracellular ﬂux assay or stress test
Acetylsalicylic acid + 1238.88 NR NR
Incorrectly predicted compounds by either assay
Metformin + 12.39 NR NR
Paraquat + 5.37 NR NR
Paroxetine + 0.13 NR NR
Primaquine + 0.60 NR NR
Promethazine + 0.07 NR NR
Sensitivity (%)
Speciﬁcity (%)
a An accurate ratio could not be determined since no toxicity was observed in glucose medihad also reported no effect on either OCR or ECAR in HepG2 cells at con-
centrations up to 1000 μM. Compounds which are identiﬁed as ETC in-
hibitors do not discriminate between complex I to IV of the ETC
therefore to identify the individual complex would involve further
mechanistic studies. It is possible to measure the activity of each of
the individual complexes using immunocaptured antibodies to the
individual complex, with the activitymeasured using an enzyme linked
immunosorbent assay (ELISA) as described previously (Nadanaciva
et al., 2007).
Acetylsalicylic acid was detected as a mitochondrial toxicant in the
Glu/Gal assay, but identiﬁed as cytotoxic in an EFA at concentrations
in excess of 1200 μM. Acetylsalicylic acid reduced the pH of the media
(data not shown) causing cytotoxicity, however in the Glu/Gal assay
this effect is circumvented by using buffered media. Previously
Nadanaciva et al. (2012) had reported no effects on OCR or ECAR at con-
centrations of 1000 μM.
Metformin, paraquat, paroxetine, primaquine and promethazine
were misclassiﬁed by both assays. The compounds metformin and
phenformin are structurally related and whilst phenformin was with-
drawn from the market due to fatal lactic acidosis, metformin has
been shown to present a much lower risk of lactic acidosis (Bando
et al., 2010).Whilstmetformin has previously been described as amito-
chondrial toxicant using a Glu/Gal approach in HepG2 cells it needs to/Gal assay, or in combination. The in vitro data prediction for both assays was based on a
ECAR and reserve capacity with the ﬁrst responding mechanism and the corresponding
own for the Glu/Gal assay. Compounds with a ratio of 3 or more are classiﬁed as positive.
Glu/Gal Combined
50 (μM) Prediction Fold change Prediction Prediction
5 + 0.6 − +
1 + 1.3 − +
.7 + 1.1 − +
.8 + 2.3 − +
.7 + 1.3 − +
.3 + 1.0 − +
1 + 1.7 − +
8 + 1.4 − +
8 + 0.9 − +
.3 + 0.5 − +
8 + 1.9 − +
− ≥3a + +
− 1.0 − −
− 1.3 − −
− 0.6 − −
− 1.4 − −
− 1.3 − −
78 41 81
100 100 100
a with no AC50 calculated. Combining both approaches gave a sensitivity of 81%.
169J. Eakins et al. / Toxicology in Vitro 34 (2016) 161–170be considered that the concentration tested was 3 mM which is in
excess of 100× Cmax (Kamalian et al., 2015). However, it has also been
reported to accumulate in the liver (Wilcock and Bailey, 1994) resulting
in higher tissue levels and exposure compared to plasma. Metformin
has been described to be a weak inhibitor of complex I only, with no ef-
fect on respiration at concentrations of 500 μM following 24 h exposure
(Dykens et al., 2008).
Paraquat haswell documented effects onmitochondria in vivo, espe-
cially in the lung, in which it is selectively taken up into alveolar epithe-
lial cells via the polyamine/putrescine transport system and undergoes
redox cycling (Smith, 1987; Gaudreault et al., 1984). It is also associated
with renal toxicity, again via transporters, in particular the human or-
ganic cation transporter, hOCT2 (Chen et al., 2007). Although described
as a complex I inhibitor in isolated brainmitochondria at 1mM, exceed-
ing 100× Cmax (Cocheme andMurphy, 2008), nomitochondrial toxicity
was reported in K562 cells using the Glu/Gal approach by Swiss et al.
(2013), which is in agreement with our ﬁndings.
Promethazine has been reported to act as an uncoupler in isolatedmi-
tochondria (Eto et al., 1985) and to accumulate in lysosomes (Nadanaciva
et al., 2011), however in this study cytotoxicity was observed in both the
Glu/Gal and EFA, shown previously in a Glu/Gal assay by Hynes et al.
(2013). Paroxetine has been described as an inhibitor of complex V
(IC50 value of 1.6 μM) using the isolated mitochondria ELISA approach
(Nadanaciva et al., 2007), in agreement with this study Rana et al.
(2011), and Swiss et al. (2013), previously using a Glu/Gal approach in
H9c2 and K562 cells respectively reported paroxetine cytotoxicity rather
than a mitochondrial toxicant. Primaquine has been described as an un-
coupler of oxidative phosphorylation in rat liver mitochondria isolated
following 14 days exposure in Charles–Foster rats (Katewa and Katyare,
2004), however neither the Glu/Gal or EFA identiﬁed this as a mitochon-
drial toxicant, in agreement with Swiss et al. (2013).
By combining the data of theGlu/Gal assay and EFA predicitivitywas
increased to a sensitivity of 81%, speciﬁcity of 100% and accuracy of 92%.
Thiswas achievedby combining the data of both assays and classifying a
mitochondrial toxicant if a compound was positive in either assay. We
have also demonstrated that with the EFA predictions on mechanism
of mitochondrial toxicity can be generated with an accuracy of 76%. In
addition, the assays presented here could also be useful tools to identify
potential drugs to target mitochondrial function to treat ischemic heart
disease, reperfusion injury (Walters et al., 2012), oncology (Gogvadze,
2011), diabetes and metabolic syndromes (Sorriento et al., 2014).
In summary this data demonstrates the use of two in vitro assays as
predictive screening tools to assess the potential of in vivomitochondri-
al toxicity, and if used early in drug discovery process could assist in
reducing late stage attrition due to adverse mitochondrial effects.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tiv.2016.03.016.
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